-
Promising COVID-19 Therapeutics(Post)
SARS-CoV-2, the causative viral agent of the novel coronavirus disease COVID-19, has sparked a global effort for creating prophylactic and therapeutic interventions. The following
NK Cell Cytotoxicity Pathway: Receptors, Signalling and Assays(Post)A natural killer cell decides by subtraction. It carries no rearranged antigen receptor and no memory of what it has seen. It presses a panel of germline-encoded receptors against a target and integr
Apoptosis Pathway: Death Receptor, Mitochondrial and Granzyme Routes(Post)Apoptosis is not one pathway but three routes into the same execution machinery. A death ligand at the surface, a mitochondrion that loses outer-membrane integrity, and a granzyme delivered by a cyto
The Research Pulse 2026: Where Biology Is Heading, According to PubMed and 300,000 Researcher Visits(Post)Research Pulse · Data study Where biology is heading: what PubMed and 300,000 researcher visits reveal We compared five years of PubMed publication counts with two years of researcher visits to Assa
CAR-T Cell Signalling Pathway: Costimulation, Output and Assays(Post)A chimeric antigen receptor is a synthetic protein wired into a real signalling pathway. The extracellular half is an antibody fragment; everything below the membrane is borrowed from the T-cell rece
Antigen Processing & Presentation(Page) Comprehensive Guide to Mononuclear Cells(Post)Immunology · Cell IsolationPeripheral Blood Mononuclear Cells (PBMCs): Composition, Isolation and UseMononuclear cells are the leukocytes with a single, unlobed nucleus — lymphocytes and monocytes. Is
SfN Neuroscience 2024(Post)SfN 2024: Meet Assay Genie at the Society for NeuroscienceAssay Genie is delighted to be attending SfN 2024 in Chicago, Illinois on 5th to the 9th of October at the McCormick Convention
BTLA: A Key Player in Immune Regulation and Cancer Therapy(Post)Introduction to BTLA in Immune Regulation B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that plays a critical role in regulating immune responses by suppressing T
Nfkb signalling pathway · HTM(Page) Tigatuzumab: Advancing Cancer Research with Targeted Therapies(Post)Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody that targets the death receptor 5 (DR5) pathway, inducing apoptosis in cancer cells.What is the mech
Nadecnemab: Advancing Cancer Research Through Anti-CD47 Targeting(Post)Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does
Regulatory T Cells and the IL-2 Paradox(Page) Senescence, the SASP and Immunosurveillance(Page) Cobolimab: Unveiling TIM-3’s Role in Cancer Immunotherapy(Post)Quick Facts About CobolimabWhat is Cobolimab?Cobolimab is a monoclonal antibody that targets TIM-3, a checkpoint protein involved in immune regulation, especially in cancer and autoimmun
Onvatilimab: Redefining the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance
Ponsegromab: A Breakthrough in Heart Failure and Cachexia Research(Post)Quick Facts About PonsegromabWhat is Ponsegromab?Ponsegromab is an investigational monoclonal antibody developed by Pfizer, primarily studied for its potential in treating heart failure
Basiliximab: Mechanism, Clinical Applications, and Research Advancements(Post)Quick Facts About BasiliximabWhat is Basiliximab?Basiliximab is a monoclonal antibody targeting the CD25 subunit of the IL-2 receptor, primarily used to prevent organ transplant rejectio
Plonmarlimab: Advancing Anti-GM-CSF Therapy in Inflammatory Diseases(Post)Quick Facts About PlonmarlimabWhat is Plonmarlimab?Plonmarlimab is a monoclonal antibody targeting GM-CSF, a cytokine involved in inflammation and immune responses.How does Plonmarlimab
Tiragolumab: Unlocking New Horizons in Cancer Immunotherapy(Post)Quick Facts About TiragolumabWhat is Tiragolumab?Tiragolumab is an anti-TIGIT monoclonal antibody developed to enhance immune responses against cancer cells. It is currently under invest